Clinical assessment, management, and rehabilitation of walking impairment in MS: an expert review

References

• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–1024. 11
   PubMed Web of Science ®Google Scholar
• Multiple sclerosis information sourcebook. New York: NY: Information Resource Center and Library of the National Multiple Sclerosis Society; 2005.
   Google Scholar
• Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013;15:146–158.
   PubMedGoogle Scholar
• Filli L, Sutter T, Easthope CS, et al. Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. Sci Rep. 2018;8:4984.
   PubMed Web of Science ®Google Scholar
• Heesen C, Haase R, Melzig S, et al. Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand. 2018;137:356–362.
   PubMed Web of Science ®Google Scholar
• Pearson M, Dieberg G, Smart N Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil. 2015;96:1339–48e7.
   PubMed Web of Science ®Google Scholar
• Bethoux F Gait disorders in multiple sclerosis. Continuum (Minneap Minn). 2013;19:1007–1022.
   PubMedGoogle Scholar
• Decavel P, Sagawa Y Jr. Gait quantification in multiple sclerosis: A single-centre experience of systematic evaluation. Neurophysiol Clin. 2019;49:165–171.
   PubMed Web of Science ®Google Scholar
• Paltamaa J, Sarasoja T, Leskinen E, et al. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil. 2007;8812:1649–1657.
   Google Scholar
• Thoumie P, Lamotte D, Cantalloube S, et al. Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler. 2005;11:485–491. 4
   PubMed Web of Science ®Google Scholar
• Stevens V, Goodman K, Rough K, et al. Gait impairment and optimizing mobility in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24:573–592.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Pozzilli C Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18:914–924.
   PubMed Web of Science ®Google Scholar
• Spain RI, St George RJ, Salarian A, et al.Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. Gait Posture. 2012;35:573–578.
   PubMed Web of Science ®Google Scholar
• Sosnoff JJ, Weikert M, Dlugonski D, et al. Quantifying gait impairment in multiple sclerosis using GAITRite technology. Gait Posture. 2011;34:145–147.
   PubMed Web of Science ®Google Scholar
• Vienne-Jumeau A, Quijoux F, Vidal PP, et al. Wearable inertial sensors provide reliable biomarkers of disease severity in multiple sclerosis: a systematic review and meta-analysis. Ann Phys Rehabil Med. 2020;63:138–147.
   PubMed Web of Science ®Google Scholar
• Givon U, Zeilig G, Achiron A Gait analysis in multiple sclerosis: characterization of temporal-spatial parameters using GAITRite functional ambulation system. Gait Posture. 2009;29,1:138–142.
   PubMed Web of Science ®Google Scholar
• Comber L, Galvin R, Coote S Gait deficits in people with multiple sclerosis: a systematic review and meta-analysis. Gait Posture. 2017;51:25–35.
   PubMed Web of Science ®Google Scholar
• Decavel P, Moulin T, Sagawa Y Jr. Gait tests in multiple sclerosis: reliability and cut-off values. Gait Posture. 2019;67:37–42.
   PubMed Web of Science ®Google Scholar
• Cofre Lizama LE, Khan F, Lee PV, et al. The use of laboratory gait analysis for understanding gait deterioration in people with multiple sclerosis. Mult Scler. 2016;22:1768–1776.
   PubMed Web of Science ®Google Scholar
• Severini G, Manca M, Ferraresi G, et al. Evaluation of clinical gait analysis parameters in patients affected by multiple sclerosis: analysis of kinematics. Clin Biomech (Bristol, Avon). 2017;45:1–8.
   PubMed Web of Science ®Google Scholar
• Davies BL, Hoffman RM, Kurz MJ Individuals with multiple sclerosis redistribute positive mechanical work from the ankle to the hip during walking. Gait Posture. 2016;49:329–333.
   PubMed Web of Science ®Google Scholar
• Ramari C, Hvid LG, David AC, et al. The importance of lower-extremity muscle strength for lower-limb functional capacity in multiple sclerosis: systematic review. Ann Phys Rehabil Med. 2020;63:123–137.
   PubMed Web of Science ®Google Scholar
• Learmonth YC, Paul L, McFadyen AK, et al. Reliability and clinical significance of mobility and balance assessments in multiple sclerosis. Int J Rehabil Res. 2012;35:69–74.
   PubMed Web of Science ®Google Scholar
• Gijbels D, Dalgas U, Romberg A, et al. Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set. Mult Scler. 2012;18:364–371.
   PubMed Web of Science ®Google Scholar
• Stellmann JP, Neuhaus A, Gotze N, et al. Ecological validity of walking capacity tests in multiple sclerosis. PLoS One. 2015;10:e0123822.
   PubMed Web of Science ®Google Scholar
• Goldman MD, Motl RW, Scagnelli J, et al. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013;81:1856–1863.
   PubMed Web of Science ®Google Scholar
• Kalron A, Menascu S, Dolev M, et al. The walking speed reserve in low disabled people with multiple sclerosis: does it provide greater insight in detecting mobility deficits and risk of falling than preferred and fast walking speeds? Mult Scler Relat Disord. 2017;17:202–206.
   PubMed Web of Science ®Google Scholar
• Sikes EM, Cederberg KL, Sandroff BM, et al. Quantitative synthesis of timed 25-foot walk performance in multiple sclerosis. Arch Phys Med Rehabil. 2020;101:524–534.
   PubMed Web of Science ®Google Scholar
• Goldman MD, Marrie RA, Cohen JA Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14:383–390.
   PubMed Web of Science ®Google Scholar
• Valet M, Quoilin M, Lejeune T, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33:1087–1099.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Reingold SC, Polman CH, et al., International advisory committee on clinical trials in multiple S. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012;11:467–476.
   PubMed Web of Science ®Google Scholar
• Gijbels D, Eijnde BO, Feys P Comparison of the 2- and 6-minute walk test in multiple sclerosis. Mult Scler. 2011;17:1269–1272.
   PubMed Web of Science ®Google Scholar
• Langeskov-Christensen D, Feys P, Baert I, et al. Performed and perceived walking ability in relation to the expanded disability status scale in persons with multiple sclerosis. J Neurol Sci. 2017;382:131–136.
   PubMed Web of Science ®Google Scholar
• Gijbels D, Alders G, Van Hoof E, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler. 2010;16:618–626.
   PubMed Web of Science ®Google Scholar
• Van Geel F, Moumdjian L, Lamers I, et al. Measuring walking-related performance fatigability in clinical practice: a systematic review. Eur J Phys Rehabil Med. 2020;56:88–103.
   PubMed Web of Science ®Google Scholar
• Leone C, Severijns D, Dolezalova V, et al. Prevalence of walking-related motor fatigue in persons with multiple sclerosis: Decline in walking distance induced by the 6-minute walk test. Neurorehabil Neural Repair. 2016;30:373–383.
   PubMed Web of Science ®Google Scholar
• Van Geel F, Veldkamp R, Severijns D, et al. Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis. Mult Scler. 2019:1352458519872465.
   Web of Science ®Google Scholar
• Cederberg KLJ, Sikes EM, Bartolucci AA, et al. Walking endurance in multiple sclerosis: meta-analysis of six-minute walk test performance. Gait Posture. 2019;73:147–153.
   PubMed Web of Science ®Google Scholar
• Feys P, Bibby BM, Baert I, et al. Walking capacity and ability are more impaired in progressive compared to relapsing type of multiple sclerosis. Eur J Phys Rehabil Med. 2015;51:207–210.
   PubMed Web of Science ®Google Scholar
• Paltamaa J, Sarasoja T, Leskinen E, et al. Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory. Phys Ther. 2008;88:176–190.
   PubMed Web of Science ®Google Scholar
• Fry D, Pfalzer L Reliability of four functional tests and rating of perceived exertion in persons with multiple sclerosis. Physiother Canada. 2006;58:212–220.
   Google Scholar
• Feys P, Bibby B, Romberg A, et al. Within-day variability on short and long walking tests in persons with multiple sclerosis. J Neurol Sci. 2014;338:183–187.
   PubMed Web of Science ®Google Scholar
• Cameron MH, Nilsagard Y Balance, gait, and falls in multiple sclerosis. Handb Clin Neurol. 2018;159:237–250.
   PubMedGoogle Scholar
• Baert I, Freeman J, Smedal T, et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study. Neurorehabil Neural Repair. 2014;28:621–631.
   PubMed Web of Science ®Google Scholar
• Sherratt RM, Bostock H, Sears TA Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature. 1980;283:570–572.
   PubMed Web of Science ®Google Scholar
• Espejo C, Montalban X Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. Clin Immunol. 2012;142:84–92.
   PubMed Web of Science ®Google Scholar
• Mainero C, Inghilleri M, Pantano P, et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology. 2004;62:2044–2050.
   PubMed Web of Science ®Google Scholar
• Baker DE Current FDA-related drug information - New drugs approved by the FDA; New dosage forms and indications approved by the FDA; Agents pending FDA approval; New drug/biologics license applications filed by manufacturer; Significant labeling changes or “dear health professional” Letters related to safety.Hosp Pharm. 2010;45:332–335.
   Google Scholar
• Hayes KC, Potter PJ, Hansebout RR, et al. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clin Neuropharmacol. 2003;26:185–192.
   PubMed Web of Science ®Google Scholar
• Jensen HB, Ravnborg M, Dalgas U, et al. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7:97–113.
   PubMed Web of Science ®Google Scholar
• Applebee A, Goodman AD, Mayadev AS, et al. Effects of dalfampridine extended-release tablets on 6-minute walk distance in patients with multiple sclerosis: a post hoc analysis of a double-blind, placebo-controlled trial. Clin Ther. 2015;37:2780–2787.
   PubMed Web of Science ®Google Scholar
• Limone BL, Sidovar MF, Coleman CI Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Health Qual Life Outcomes. 2013;11:105.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Hyland M Dalfampridine in multiple sclerosis. Drugs Today (Barc). 2010;46:635–639.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732–738.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71:1134–1141.
   PubMed Web of Science ®Google Scholar
• Zorner B, Filli L, Reuter K, et al. Prolonged-release fampridine in multiple sclerosis: improved ambulation affected by changes in walking pattern. Mult Scler. 2016;22:1463–1475.
   PubMed Web of Science ®Google Scholar
• Gasperini C, Hupperts R, Lycke J, et al. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: item-level analysis of the MSIS-29. J Neurol Sci. 2016;370:123–131.
   PubMed Web of Science ®Google Scholar
• Filli L, Werner J, Beyer G, et al. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis. Eur J Neurol. 2019;26:281–289.
   PubMed Web of Science ®Google Scholar
• Sammaraiee Y, Yardley M, Keenan L, et al. Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. Mult Scler Relat Disord. 2019;27:95–100.
   PubMed Web of Science ®Google Scholar
• Sadiq SA, Wang GC Long–term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006;253:563–569.
   PubMed Web of Science ®Google Scholar
• Arroyo Gonzalez R A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert Rev Neurother. 2018;18:785–791.
   PubMed Web of Science ®Google Scholar
• Lee BS, Jones J, Lang M, et al. Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis. J Neurosurg. 2018;129:1056–1062.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–441.
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451–459.
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122–1131.
   PubMed Web of Science ®Google Scholar
• Akgun K, Essner U, Seydel C, et al. Daily practice managing resistant multiple sclerosis spasticity with delta-9-tetrahydrocannabinol: cannabidiol oromucosal spray: a systematic review of observational studies. J Cent Nerv Syst Dis. 2019;11:1–18.
   Web of Science ®Google Scholar
• Coghe G, Pau M, Corona F, et al. Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol. 2015;262:2472–2477.
   PubMed Web of Science ®Google Scholar
• Cameron MH, Wagner JM Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep. 2011;11:507–515.
   PubMed Web of Science ®Google Scholar
• Manago MM, Glick S, Hebert JR, et al. Strength training to improve gait in people with multiple sclerosis: a critical review of exercise parameters and intervention approaches. Int J MS Care. 2019;21:47–56.
   PubMedGoogle Scholar
• Sanchez-Lastra MA, Martinez-Aldao D, Molina AJ, et al. Pilates for people with multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;28:199–212.
   PubMedGoogle Scholar
• Cramer H, Lauche R, Azizi H, et al. Yoga for multiple sclerosis: a systematic review and meta-analysis. PLoS One. 2014;9:e112414.
   PubMedGoogle Scholar
• Pau M, Corona F, Coghe G, et al. Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial. Disabil Rehabil. 2018;40:144–151.
   PubMed Web of Science ®Google Scholar
• Campbell E, Coulter EH, Paul L High intensity interval training for people with multiple sclerosis: A systematic review. Mult Scler Relat Disord. 2018;24:55–63.
   PubMed Web of Science ®Google Scholar
• Dalgas U, Langeskov-Christensen M, Stenager E, et al. Exercise as medicine in multiple sclerosis-time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr Neurol Neurosci Rep. 2019;19:88.
   PubMed Web of Science ®Google Scholar
• Baird JF, Sandroff BM, Motl RW Therapies for mobility disability in persons with multiple sclerosis. Expert Rev Neurother. 2018;18:493–502.
   PubMed Web of Science ®Google Scholar
• Vaney C, Gattlen B, Lugon-Moulin V, et al. Robotic-assisted step training (lokomat) not superior to equal intensity of over-ground rehabilitation in patients with multiple sclerosis. Neurorehabil Neural Repair. 2012;26:212–221.
   PubMed Web of Science ®Google Scholar
• Robinson AG, Dennett AM, Snowdon DA Treadmill training may be an effective form of task-specific training for improving mobility in people with Parkinson’s disease and multiple sclerosis: a systematic review and meta-analysis. Physiotherapy. 2019;105:174–186
   PubMed Web of Science ®Google Scholar
• Newman MA, Dawes H, van den Berg M, et al. Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: a pilot study. Mult Scler. 2007;13:113–119.
   PubMed Web of Science ®Google Scholar
• Feys P, Straudi S Beyond therapists: technology-aided physical MS rehabilitation delivery. Mult Scler. 2019;25:1387–1393.
   PubMed Web of Science ®Google Scholar
• Afzal T, Tseng SC, Lincoln JA, et al. Exoskeleton-assisted gait training in persons with multiple sclerosis: a single-group pilot study. Arch Phys Med Rehabil. 2020;101:599–606.
   PubMed Web of Science ®Google Scholar
• Swinnen E, Baeyens JP, Pintens S, et al. Trunk kinematics during walking in persons with multiple sclerosis: the influence of body weight support. NeuroRehabilitation. 2014;34:731–740.
   PubMed Web of Science ®Google Scholar
• van Kammen K, Boonstra AM, van der Woude LH, et al. The combined effects of guidance force, bodyweight support and gait speed on muscle activity during able-bodied walking in the Lokomat. Clin Biomech (Bristol, Avon). 2016;36:65–73.
   PubMed Web of Science ®Google Scholar
• Lefeber N, De Keersmaecker E, Henderix S, et al. Physiological responses and perceived exertion during robot-assisted and body weight-supported gait after stroke. Neurorehabil Neural Repair. 2018;32:1043–1054.
   PubMed Web of Science ®Google Scholar
• Lefeber N, Swinnen E, Kerckhofs E The immediate effects of robot-assistance on energy consumption and cardiorespiratory load during walking compared to walking without robot-assistance: a systematic review. Disabil Rehabil Assist Technol. 2017;12:657–671.
   PubMed Web of Science ®Google Scholar
• Beer S, Aschbacher B, Manoglou D, et al. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler. 2008;14:231–236.
   PubMed Web of Science ®Google Scholar
• Lo AC, Triche EW Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. Neurorehabil Neural Repair. 2008;22:661–671.
   PubMed Web of Science ®Google Scholar
• Straudi S, Fanciullacci C, Martinuzzi C, et al. The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial. Mult Scler. 2016;22:373–384.
   PubMed Web of Science ®Google Scholar
• Schwartz I, Sajin A, Moreh E, et al. Robot-assisted gait training in multiple sclerosis patients: a randomized trial. Mult Scler. 2012;18:881–890.
   PubMed Web of Science ®Google Scholar
• Straudi S, Benedetti MG, Venturini E, et al. Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial. NeuroRehabilitation. 2013;33:555–563.
   PubMed Web of Science ®Google Scholar
• Straudi S, Manfredini F, Lamberti N, et al. Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): a randomized controlled trial. Mult Scler. 2020;26:716–724.
   PubMedGoogle Scholar
• Seebacher B, Kuisma R, Glynn A, et al. Rhythmic cued motor imagery and walking in people with multiple sclerosis: a randomised controlled feasibility study. Pilot Feasibility Study. 2015;1:25.
   PubMedGoogle Scholar
• Decety J Do imagined and executed actions share the same neural substrate? Brain Res Cogn Brain Res. 1996;3:87–93.
   PubMedGoogle Scholar
• Jackson PL, Lafleur MF, Malouin F, et al. Potential role of mental practice using motor imagery in neurologic rehabilitation. Arch Phys Med Rehabil. 2001;82:1133–1141.
   PubMed Web of Science ®Google Scholar
• Hanson M, Concialdi M Motor imagery in multiple sclerosis: exploring applications in therapeutic treatment. J Neurophysiol. 2019;121:347–349.
   PubMed Web of Science ®Google Scholar
• Moumdjian L, Sarkamo T, Leone C, et al. Effectiveness of music-based interventions on motricity or cognitive functioning in neurological populations: a systematic review. Eur J Phys Rehabil Med. 2017;53:466–482.
   PubMed Web of Science ®Google Scholar
• Conklyn D, Stough D, Novak E, et al. A home-based walking program using rhythmic auditory stimulation improves gait performance in patients with multiple sclerosis: a pilot study. Neurorehabil Neural Repair. 2010;24:835–842.
   PubMed Web of Science ®Google Scholar
• Shahraki M, Sohrabi M, Taheri Torbati HR, et al. Effect of rhythmic auditory stimulation on gait kinematic parameters of patients with multiple sclerosis. J Med Life. 2017;10:33–37.
   PubMedGoogle Scholar
• Seebacher B, Kuisma R, Glynn A, et al. The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial. Mult Scler. 2017;23:286–296.
   PubMedGoogle Scholar
• Moumdjian L, Moens B, Maes PJ, et al. Walking to music and metronome at various tempi in persons with multiple sclerosis: a basis for rehabilitation. Neurorehabil Neural Repair. 2019;33:464–475.
   PubMed Web of Science ®Google Scholar
• Veldkamp R, Baert I, Kalron A, et al. Structured cognitive-motor dual task training compared to single mobility training in persons with multiple sclerosis, a multicenter RCT. J Clin Med. 2019;8,12.
   Web of Science ®Google Scholar
• Wening J, Ford J, Jouett LD Orthotics and FES for maintenance of walking in patients with MS. Dis Mon. 2013;59:284–289.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Marazzini F, Crippa A, et al. Do static or dynamic AFOs improve balance? Clin Rehabil. 2002;16:894–899.
   PubMed Web of Science ®Google Scholar
• Sutliff MH, Naft JM, Stough DK, et al. Efficacy and safety of a hip flexion assist orthosis in ambulatory multiple sclerosis patients. Arch Phys Med Rehabil. 2008;89:1611–1617.
   PubMed Web of Science ®Google Scholar
• Miller L, McFadyen A, Lord AC, et al. Functional electrical stimulation for foot drop in multiple sclerosis: a systematic review and meta-analysis of the effect on gait speed. Arch Phys Med Rehabil. 2017;98:1435–1452.
   PubMed Web of Science ®Google Scholar
• Abboud H, Hill E, Siddiqui J, et al. Neuromodulation in multiple sclerosis. Mult Scler. 2017;23:1663–1676.
   PubMedGoogle Scholar
• Beauchamp MK, Skrela M, Southmayd D, et al. Immediate effects of cane use on gait symmetry in individuals with subacute stroke. Physiother Can. 2009;61:154–160
   PubMed Web of Science ®Google Scholar